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ABSTRACT 
 
Aims  Semi-synthetic derivatives of the anti-malarial drug artemisinin may also possess anti-cancer 
properties. The ability to detect artemisinin uptake and distribution in cells would facilitate live cell 
imaging without labelling. This study describes mid-range infrared absorption spectra for three 
artemisinin variants and attempts to detect their presence in a simple cell model (erythrocytes). 
Cytotoxicity assays assess potential anti-cancer properties against bladder cancer cells.   
 
Methods  Mid-range Fourier transform infrared spectra were obtained from dry preparations of 
Dihydroartemisinin (DHA), Artesunate (ART) and Artemether (ARTE).  Erythrocytes were prepared 
from normal blood and incubated for 30 minutes at 37°C with the three artemisinin derivatives. 
Cytospin preparations were prepared on aluminium foil for spectroscopy. Potential for growth 
inhibition in the RT112 bladder carcinoma cell line was assessed by the 3-(4,5-Dimethylthiazol-2-
yl)-2,5-Diphenyltetrazolium Bromide residual viable biomass method. 
 
Results  Spectra were obtained from the three native compounds. Repeat scans after 8 weeks 
showed ART and ARTE to be stable, stored under manufacturer’s recommendations.  DHA 
exhibited marked changes over the same period.  It was possible by subtraction to detect DHA in 
cytospins, but not ART or ARTE.  The fit between the subtraction spectrum and that of the native 
compound was >80%. DHA and ART showed strong cytotoxic potential against RT112 cells. 
 
Conclusion  The artemisinin derivatives tested exhibit unique mid-range infrared absorption 
spectra which can be used to monitor degradation and, for DHA, can be detected by subtraction in 
loaded erythrocytes rendering future imaging studies feasible. Its cytotoxic efficacy against RT112 
cells suggest bladder cancer as a possible target disease. 
 
WHAT THE PAPER ADDS   
The spectra have been added to databases where they had not previously been represented.  The 
ability to detect dihydroartemisinin in erythrocytes by Fourier transform infrared methodology is a 
step towards imaging studies in live cells that would expand options for tracking the compound in 
its native state, without the disadvantages of labelling. The demonstration of cytotoxicity against 
bladder cancer cells is original and enhances the relevance of the study.
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INTRODUCTION 
Artemisinin is derived from the sweet wormwood plant Artemisia annua L and has a long history 
of use in Chinese medicine to treat febrile conditions [1]. It is a key component of the World 
Health Organisation’s global anti-malaria strategy, its derivatives representing a class of highly 
potent anti-malarial drugs. Following success against malaria, originally under the Chinese name, 
Qinghaosu [2] and subsequently as artemisinin [3], researchers began investigating whether 
artemisinins held potential anticancer properties.  Early reports demonstrating that artemisinins 
were cytotoxic to tumour cells include experiments with neuronal cells [4] and a range of cancer 
cells [5]. Subsequent studies have demonstrated, growth inhibition, increased levels of oxidative 
stress, enhanced apoptosis and inhibition of angiogenesis on exposure to these drugs [6-8]. Some 
of these properties and mechanisms are outlined below.  
 
Artemisinins are lipophilic and can cross erythrocytic, parasitic and host cell plasma membranes 
[9] as well as cytoplasmic membrane bound organelles such as mitochondria [10]. The mechanism 
of artemisinins’ activity is known to be dependent upon the Fe2+ mediated oxidization of the 
atypical endoperoxide bridge [11].  In nucleate cells artemisinins induce apoptosis by a ROS 
mediated activation loop among caspases 8 and 9 [12] and, optionally also caspase 3 [13]. Semi-
synthetic artemisinin derivatives have been formulated to increase solubility and bioavailability in-
vivo.  However, artemisinins are metabolised quickly, so while their rapid activity makes them 
effective against malaria, the use of artemisinin for cancer treatment/anti-angiogenesis treatment 
may be limited by its fast elimination from blood plasma, unless slow-release or combination 
strategies [14] can be developed.  
 
Current malarial therapies and investigations into potential anti-cancer properties are based on 
the derivatives Dihydroartemisinin (DHA), Artesunate (ART) and Artemether (ARTE) [15].  An aid to 
research in this area would be an ability to image cellular uptake and distribution in real time, as 
demonstrated with fluorescence labeling [10]. This prompted us to design a laboratory-based 
study investigating artemisinin identification by Fourier transform infrared (FT-IR) spectroscopy, 
offering a label-free reporting system. These initial studies use a relatively simple erythrocyte 
model, but may represent the beginning of a body of work that ultimately facilitates live cell FT-IR 
imaging of neoplastic epithelial cells treated with native artemisinin derivatives, enabling a clearer 
understanding of their uptake, trafficking and metabolism and hence their potential value as 
adjuvant components of targeted cancer therapies. 3  
MATERIALS AND METHODS 
 
In vitro analysis of raw materials 
DHA was packaged in foil and stored below 5oC according to the manufacturer’s instructions.  The 
ART and ARTE derivatives were indicated for storage in plastic at room temperature. FT-IR 
spectroscopy was conducted for each artemisinin derivative using a FT-IR Nexus analyser (Thermo 
Nicolet, USA) and interpreted by OMNIC (version 6.1) software. A background signal was collected 
and subtracted from sample signatures. For analysis of the compounds ex-vivo, enough crystals to 
adequately cover the diamond within the sample inlet were held securely in place by a metal 
clamp. A spectrum was acquired on screen within one minute. The resultant plots showed the 
absorption and wave number of the peaks identified.  These were compared to patterns 
characteristic of specific bonds to determine if a unique spectrum for artemisinin derivatives could 
be identified using information from the following online sources, Byrd J [16] and the Chemical 
Education Digital Library [17]. 
 
Incorporation of DHA into viable erythrocytes and its identification in situ 
Enucleate Erythrocytes were used to pilot in-vivo detection, being a simple cell type, as well as 
relevant to the original use of the drugs. They were obtained from a finger-prick into 10ml 
phosphate buffered saline (PBS) and washed twice by centrifugation. The artemisinin derivatives 
ART, DHA and ARTE were used. 0.2g of each derivative was dissolved into 2ml of absolute ethanol.  
20µl of each artemisinin stock solution was added to 2ml of Erythrocytes in PBS, 2ml was kept as 
control. These were incubated with the derivatives for 30 minutes in a cell culture incubator (37oC, 
5% CO2 in humidified air). They were then centrifuged at 1200g for 5 minutes. The supernatant 
was removed and the cells were re-suspended in PBS and re-centrifuged. The resulting pellet was 
used to prepare cytospin slides. 
 
Labeled slides were wrapped in aluminium foil, shiny-side-out, and placed in a cytospin centrifuge 
(Cytospin 4, Thermo Scientific, UK). The Erythrocytes pellets were added to the sample inlets on 
the cytospin filter and centrifuged at 1000rpm for 5 minutes. Slides were air-dried before spectra 
were obtained by forcing  the blood spots onto the diamond crystal of the FT-IR analyser.  A 
background spectrum for the aluminium foil was subtracted. OMNIC software was then used to 
subtract the untreated Erythrocyte spectrum from spectra obtained from cells treated with each 
artemisinin derivative. This provided three subtraction spectra with which to search against online 4  
libraries.  
 
Cytotoxicity to epithelial monolayers 
Cytotoxicity studies were performed according to the protocols used in previous studies from the 
group and set out in detail elsewhere [18].  Briefly, cells were seeded into 96-well plates, allowed to 
attach for 24 hours, treated with serial dilutions of drug, incubated further for 48 hours and the 
residual viable biomass assessed by the addition of 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) reagent for 2 hours before measuring absorbance at 470nm on 
a plate-reading spectrophotometer.  
 
Statistical analysis 
Statistical analyses were performed using SPSS software (version 19.0 for Windows; SPSS Inc., 
Chicago, Illinois, USA). Data were normally distributed, thus descriptive statistics are expressed as 
mean ± standard errors of the mean. Data was subjected to a one-way analysis of variance 
(ANOVA), providing an overall figure of significance. In order to ascertain where the differences 
are and discover trends post hoc analysis the Tukey or Games-Howell tests were applied. The 
conventional p<0.05 value was used as the cut-off for significance. 
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RESULTS 
 
In vitro results on raw materials 
The first spectrum obtained for DHA is shown in figure 1. The very large peak at ~2450cm-1 can be 
ignored as being carbon dioxide interference from the atmosphere. This peak has been blanked 
out in subsequent spectra. The peak at 3245cm-1 corresponds to the O-H bond within the DHA 
molecule, which is added to native artemisinin to form DHA and improve the solubility of the drug.  
The peak at 2921.95cm-1 corresponds to C-H bonding. There is a peak at 1750cm-1 that 
corresponds to a carbonyl C=O bond indicative of an aldehyde, amide, carboxylic acid or ester. 
Within the fingerprint region there are peaks between 180 and 1300cm-1, these correspond to the 
ether, C-O-C bonds within the molecule.  
 
A new spectrum was obtained for DHA 52 days after the first; changes had occurred as shown in 
figure 2.  The OH region became broader and formed a doublet, usually seen when a molecule 
contains both O-H and N-H bonding, which DHA should not. This change is indicative of 
degradation and may be due to moisture reacting with the O-H bonds during storage.  Spectra for 
ART and ARTE were subsequently also obtained 14 days later (Day 66).  They do not display such 
differences.  Sample spectra are shown in figures 3 and 4.   
 
Figure 3 consists of two spectra for ART taken eight weeks apart. The spectra do not have the 
degree of change seen with the DHA. There is some change in the C-H bond section just under 
3000cm-1. ART was synthesised to be more water soluble and has a carboxylic acid group, 
corresponding peaks seen at 1142/1144.53cm-1, an additional ether C-O-C bond (smaller peaks 
between 1080 and 1300cm-1), plus an ester bond O=C-O.   
 
ARTE plots show little change with time (Figure 4).  ARTE is a lipophilic alkylether without an OH 
group, so there is no peak between 3200 and 3600cm-1. There is a large peak that corresponds to 
C-H bonding between 2850 and 3000cm-1. ARTE does not have a carbonyl C=O bond therefore 
there is no peak between 1690-1760cm-1. It has an additional methyl CH3 group; this may 
correspond to the peaks at 1373/1372cm-1, respectively. The CH3 is attached to an O, so there is a 
significant amount of C-O-C ether bonds, which can be seen in the peaks between 1080 and 
1300cm-1.  
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OMNIC 6.1 software was used to confirm whether the DHA, ART and ARTE spectra matched 
spectra of molecules stored within online databases/libraries. Matches were not found, indicating 
their spectra are unique. A new library was set up containing the spectra for each of the 
artemisinin derivatives. 
 
Incorporation of DHA into viable erythrocytes and its identification in situ 
For the ART and ARTE subtraction spectra, no strong matches were found. For the DHA treated 
cells a match of 80.87% with the spectra obtained after subtraction for the pure DHA compound 
(Figure 5).   
 
Cytotoxicity to epithelial monolayers 
All three artemisinin derivatives showed significant (P<0.05 vs control) toxicity studies using 
RTT112 bladder cancer cells in an MTT-based assay over 1.5µg/ml, but the curves for ARTE were 
flatter than for ART or DHA with respective R2 values of 0.67, 0.74 and 0.96 (Figure 6). ARTE failed 
to achieve a reduction in residual viable biomass to 50% of control values (IC50) up to 25µg/ml.  
IC50s for ART and DHA were 3µg/ml and 9µg/ml, respectively.  
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DISCUSSION 
Semi-synthetic derivatives of the anti-malarial drug artemisinin may possess cytotoxic activity 
against nucleate cells growing in vitro, and anti-angiogenic activity [4,5], offering potential anti-
cancer properties. To further the study of these phenomena the ability to detect artemisinin 
uptake and distribution in cells would be advantageous. Live cell imaging studies without the 
problems of labelling small molecules could be achieved through FT-IR spectroscopy.  This study 
describes mid-range infrared absorption spectra for three artemisinin variants and detects the 
presence of one, DHA, in erythrocytes incubated with the drugs, albeit at this stage without 
imaging. It also assesses the cytotoxic effect of artemisinin derivatives in the RT112 bladder 
carcinoma cell line. 
 
The structurally unique feature and key source of artemisinins activity is its endoperoxide bridge. 
However, as there is no net change in the dipole moment during the vibration of homonuclear 
molecules such as O2, N2, and H2, these molecules do not absorb IR radiation [19]. Therefore, the 
characteristic O-O bond within the endoperoxide bridge is unlikely to absorb IR and will not 
contribute a characteristic peak to the spectra for artemisinins.  With that said, the spectra 
obtained still appeared to be unique and were not found within existing spectral databases. The 
1750cm-1 C=O peak does not fit with the structure of DHA. Wild-type artemisinin does however 
have a C=O bond and this may suggest a level of impurity during the synthesis of DHA.   
 
The Erythrocytes experiment indicated artemisinin derivatives spectra were potentially 
identifiable within a complex environment.  The high dose used for this experiment is far in excess 
of those used elsewhere in the study or are attainable therapeutically, but follow a conventional 
progression in experimentation, starting with a strong effect that must be achievable for the 
system to show potential.  Concentrations will subsequently be lowered to find threshold 
detection levels. The subtraction spectra of DHA in Erythrocytes achieved an 80.87% match with 
the spectrum for pure DHA, so some of the compound entered the cells remaining relatively 
unaltered. This may be due to a lack of free Fe2+ within the ‘normal’ Erythrocytes.  It is noteworthy 
that DHA was the most cytotoxic of the three derivatives towards RTT112 bladder cancer cells in 
log phase growth. For ART and ARTE no match was found, indicating that the compounds may not 
have entered the Erythrocytes at all, or had been modified beyond recognition by metabolic 
processes. The former possibility is arguably more likely, as Erythrocytes contain limited capacity 
for active metabolism. 8  
Identifying the spectra of artemisinins within more metabolically active nucleate cells introduces 
several factors that require consideration and further study. Firstly, as the concentrations of the 
artemisinin derivatives present are far smaller and much harder to identify within a mixture, a 
range of different concentrations more closely approximating to clinically achievable plasma 
values than used here, should be applied to cells to assess the concentration limits for detection. 
Among the highest human plasma concentrations reported in the literature is 443ng/ml [20] 
compared with the 1mg/ml applied to the washed erythrocytes in-vitro here. Secondly, a range of 
cell lines could be used to demonstrate differences in uptake and detection. Thirdly, artemisinins 
are reactive, with a short half-life in-vivo.  Oral artemisinins have been credited with a mean 
absorption time of 0.78 hours [21] and a residence time of 3.3hr.  This compares unfavourably 
(32%) with bioavailability from intramuscular injection in oil.  However, the mean residence time 
of the latter (10.6h) was three times longer than following oral administration.  Gordi et al [22] 
quotes a half-life of 0.7h and hepatic extraction ratio of 0.87.  When applying the derivatives to 
cells, key bonds may break (e.g., cleavage of the peroxide bridge) changing the molecular structure 
and altering the absorbance spectrum. Time series during exposure of live cells to drug may yield 
information on turnover as we have shown using time-lapse fluorescence in other contexts [23]. It 
may also with artemisinins, in the first instance be possible to tag the derivatives with a 
fluorochrome to allow parallel detection through fluorescent microscopy, adding validity to the 
images from a well-established method. Of course, the handling of a compound may be influenced 
by the label; circumventing that issue is an important driver towards IR imaging.  
 
Uptake in erythrocytes is a first step towards detection in tissues and ultimately live cells.  In this 
study it has already thrown up differences in detectability between the three variants used.  There 
are also variations in cytotoxicity against RT112 cells, with artemether proving markedly less toxic.  
The focus on bladder cancer reflects the interests of our group, but as noted in the introduction, 
activity against other cancer cells has been demonstrated (4,5).  Investigating the uptake and 
processing of artemisinins within cancer cells is therefore worthy of study and would ideally 
involve applying live cell imaging techniques [24] to provide valuable information in real time, 
particularly if rapid acquisition is possible using limited spectral information -for example on a 
QCL-based instrument [25]. 
 
TAKE-HOME MESSAGE 
This first demonstration that DHA uptake can be detected by its presence in erythrocytes using FT-9  
IR spectroscopy, offers the possibility of localising the drug in fixed or potentially live cells without 
labelling, using IR imaging equipment.  The failure to detect the other analogues may indicate their 
speedy intracellular metabolism and might shed light on the differences in cytotoxicity that clearly 
exist between the analogues, at least to the RT112 cell line in-vitro. 
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LEGENDS TO FIGURES 
 
 
Figure 1: Original DHA spectrum (Day 0) 
FT-IR spectrum of DHA crystals on aluminium foil. The large peak at ~2450cm-1 is considered to be 
interference from carbon dioxide in the atmosphere and has been blanked out in subsequent 
spectra. 
 
Figure 2: Spectra for DHA obtained on (Day 52) 
Considerable changes have occurred since Day 0, notably the OH region broadening into a doublet, 
indicating O-H and N-H bonding.  
 
Figure 3: FT-IR absorption spectra for ART  
Two spectra are shown, obtained on Day 0  (upper) and the following Day 66 (lower). The Spectra 
do not have the degree of change seen with DHA. There is some change in the C-H bond section just 
under 3000cm-1. 
 
Figure 4: The FT-IR absorption spectra for ARTE 
Two spectra, taken on Day 0  (upper) and the following Day 66 (lower).  These show little change. 
ARTE is without an OH group or carbonyl bond, so there are no peaks between 3200 and 3600cm-
1 or  1690-1760cm-1. It has an additional methyl CH3 group, perhaps corresponding to the peaks at 
1373/1372cm-1.  
 
Figure 5: Subtraction and library search spectra for RBCs treated with DHA 
Lower plot – spectrum from ART ex-vivo.  Upper plot – subtraction of erythrocyte spectrum from 
DHA-loaded erythrocytes. 
  
Figure 6: Toxicity of DHA, ART and ARTE to RT112 cells 
MTT assay: Residual Viable Biomass as % control (OD experimental / OD control x 100) plotted as 
means ±SEM (n=8) against concentration of drug. 
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